The Global Health Body Issues Alert Over Critical Lack of Obesity Injections

Less than 10% of people eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it releases its inaugural recommendations on the drugs.

With more than one billion people worldwide now obese, it is calling for increased and just availability to GLP-1 medication.

Based on estimates, over two billion will be obese by 2030 unless action is taken.

"The latest guidelines acknowledges that obesity is a chronic disease that can be addressed with thorough and lifelong care," said its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant obstacles to widespread availability to the treatments that can assist patients in reducing significant body mass, says the body.

GLP-1 Therapy Scarcity

Despite the present most favorable outlook, the production of these medications could only cover around 100 million people – less than 10% of the global need, according to the health organization.

The recommendation encourages governments and firms to expand access, through approaches such as licensing agreements.

The intellectual property rights on semaglutide – the core ingredient of a leading brand – is set to lapse in several nations in 2026.

How Obesity Jabs Function

The injections mimick a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so individuals eat less.

Individuals typically see weight reduction within a few weeks of commencing the regular doses.

Evidence indicates users may regain a significant portion within a year of stopping the treatment, because their normal food cravings return.

Being overweight or obese elevates your risk for developing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.

Excess weight concerns individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.